SCHEMBL8623669

SCHEMBL8623669

Fc1ccc(C#Cc2ccc(Br)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
GRM5 P41594 4/20 0.42
FFAR1 O14842 1/20 0.42
CYP2A6 P11509 1/20 0.42
GPR183 P32249 2/20 0.39
APP P05067 3/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ACACB O00763 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 2/20 0.35
CTSL P07711 1/20 0.35
STAT1 P42224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7717366 0.86 GRM5 (0.50) MAPTGRM5FFAR1APP
SCHEMBL1246271 0.86 CYP2A6 (0.57) MEN1KMT2ALMNAMAPTMAPK1
SCHEMBL10300106 0.86 GRM5 (0.50) MAPTGRM5FFAR1APP
SCHEMBL718949 0.86 GRM5 (0.50) MAPTGRM5FFAR1APP
SCHEMBL20015760 0.86 CYP2A6 (0.57) MEN1KMT2ALMNAMAPTMAPK1
Charcoal, Activated SCHEMBL31286307 0.83 GRM5 (0.48) MAPTGRM5FFAR1APP
Fluoride SCHEMBL31286313 0.83 GRM5 (0.48) MAPTGRM5FFAR1APP
SCHEMBL7026005 0.83
SCHEMBL1622 0.83
Fluoride SCHEMBL25376004 0.80 CYP2A6 (0.57) SMN1; SMN2MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 EP disclosed
EP-0648723-B1 Diphenylacetylene compound, process for preparing the same and liquid crystal composition and element comprising the same SUMITOMO CHEMICAL CO (JP) 1998-05-20 EP disclosed
US-5658489-A EXCELLENT ANISOTROPY OF REFRACTIVE INDEX; LOW VISCOSITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-08-19 US disclosed
EP-0648723-A1 Diphenylacetylene compound, process for preparing the same and liquid crystal composition and element comprising the same SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1995-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS SMN1; SMN2 4815/4885MEN1 3943/4885KMT2A 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.